secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-06-16T20:30:16+00:00
Accession:  0001628280-26-043559
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas, Pfizer, Rigel close VEPPANU license deal; $70M upfront received
------------------------------------------------------------------------

- HSR waiting period terminated June 11, 2026, making License Agreement effective.
- Rigel paid $70M aggregate upfront to Arvinas and Pfizer, split evenly.
- Additional $15M payable upon successful completion of transition activities.
- Up to $320M in development, regulatory, and commercial milestones plus tiered royalties.
- Milestones and royalties replace unearned payments from Pfizer to Arvinas under prior collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/0001628280-26-043559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/arvn-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-043559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer